Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) EBIT (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed EBIT for 16 consecutive years, with -$40.4 million as the latest value for Q4 2025.

  • Quarterly EBIT fell 292.58% to -$40.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$151.2 million through Dec 2025, down 271.79% year-over-year, with the annual reading at -$151.2 million for FY2025, 271.79% down from the prior year.
  • EBIT hit -$40.4 million in Q4 2025 for Vanda Pharmaceuticals, down from -$31.3 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $12.4 million in Q2 2021 to a low of -$41.0 million in Q1 2025.
  • Historically, EBIT has averaged -$7.9 million across 5 years, with a median of -$6.5 million in 2023.
  • Biggest five-year swings in EBIT: soared 8372.8% in 2021 and later tumbled 560.83% in 2024.
  • Year by year, EBIT stood at $8.6 million in 2021, then dropped by 23.24% to $6.6 million in 2022, then tumbled by 207.01% to -$7.1 million in 2023, then plummeted by 44.9% to -$10.3 million in 2024, then plummeted by 292.58% to -$40.4 million in 2025.
  • Business Quant data shows EBIT for VNDA at -$40.4 million in Q4 2025, -$31.3 million in Q3 2025, and -$38.5 million in Q2 2025.